Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations

MADISON, Wis., July 20, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), an oncology-focused biotechnology company, today announces the appointment of Jarrod...
June 23, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer

MADISON, Wis., June 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), an oncology-focused biotechnology company, today announces the results of the first...
June 15, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel

MADISON, Wis., June 15, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), an oncology-focused biotechnology company, today announces the results of a preliminary...
May 31, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform

MADISON, Wis., May 31, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that the United States Patent...
May 25, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel

MADISON, Wis., May 25, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the Company”), an oncology-focused biotechnology company, today announces that the United States Patent...
May 24, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 5th Annual SeeThru Equity Microcap Investor Conference

MADISON, Wis., May 24, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the...
May 23, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 2016 Marcum MicroCap Conference

MADISON, Wis., May 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the...
May 20, 2016 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO

MADISON, Wis., May 20, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the Company), an oncology-focused biotechnology company, today announces that its previously filed...
May 16, 2016 16:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Satisfies All Nasdaq Listing Criteria

MADISON, Wis., May 16, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or the "company"), an oncology-focused biotechnology company, announces today that on May...
May 12, 2016 16:15 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces First Quarter 2016 Financial Results

MADISON, Wis., May 12, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces its financial results for the first quarter of...